A Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine

Basit Öğe Kaydı
dc.authorid0000-0002-5770-344X
dc.authorscopusid29067508300
dc.authorscopusid27967486000
dc.authorscopusid57195962064
dc.authorscopusid57195959817
dc.authorwosidBEYAZYUZ, MURAT/ABA-7934-2020
dc.authorwosidAlbayrak, Yakup/ABA-7651-2020
dc.contributor.authorAlbayrak, Yakup
dc.contributor.authorBeyazyüz, Murat
dc.contributor.authorAbbak, Özlem
dc.contributor.authorAltındağ, Ece
dc.date.accessioned2022-05-11T14:41:07Z
dc.date.available2022-05-11T14:41:07Z
dc.date.issued2019
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Ruh Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.description.abstractRabbit Syndrome is an uncommon side effect of antipsychotic treatment. Although it is usually associated with typical antipsychotics, it can also be related to atypical antipsychotics. Anticholinergics are the most accepted treatment approach in treating Rabbit Syndrome. Fluvoxamine is a member of selective serotonin reuptake inhibitors and it is a potent agonist of sigma 1 receptors. In this article, we report a Rabbit Syndrome case who has benefited from fluvoxamine, in terms of both depressive disorder and Rabbit Syndrome; and present the data on the effects of sigma 1 agonist fluvoxamine on numerous movement disorders.
dc.identifier.doi10.9758/cpn.2019.17.1.134
dc.identifier.endpage138
dc.identifier.issn1738-1088
dc.identifier.issn2093-4327
dc.identifier.issue1en_US
dc.identifier.pmid30690950
dc.identifier.scopus2-s2.0-85060800970
dc.identifier.scopusqualityQ2
dc.identifier.startpage134
dc.identifier.urihttps://doi.org/10.9758/cpn.2019.17.1.134
dc.identifier.urihttps://hdl.handle.net/20.500.11776/9068
dc.identifier.volume17
dc.identifier.wosWOS:000455924800016
dc.identifier.wosqualityQ3
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorAlbayrak, Yakup
dc.institutionauthorBeyazyüz, Murat
dc.institutionauthorAbbak, Özlem
dc.institutionauthorAltındağ, Ece
dc.language.isoen
dc.publisherKorean Coll Neuropsychopharmacology
dc.relation.ispartofClinical Psychopharmacology and Neuroscience
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectRabbit syndrome
dc.subjectSigma receptors
dc.subjectSide effect
dc.subjectFluvoxamine
dc.subjectSerotonin Reuptake Inhibitors
dc.subjectClinical-Implications
dc.subjectTardive-Dyskinesia
dc.subjectReceptor Agonists
dc.subjectChaperone
dc.subjectLigands
dc.subjectCortex
dc.subjectBrain
dc.subjectScale
dc.titleA Report of Rabbit Syndrome Who Benefited from Sigma 1 Agonist Fluvoxamine
dc.typeEditorial

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
9068.pdf
Boyut:
186.9 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Tıp Fakültesi Koleksiyonu